Trastuzumab Deruxtecan in Advanced Breast Cancer

Sponsor
Wenjin Yin
Study ID
NCT07180264
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Breast Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab deruxtecan — DRUG
    Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.

Study Details

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Key Dates

Start date
Aug 28, 2025
Status verified
Nov 2025
Primary completion
Feb 28, 2027
Completion
Feb 28, 2029

Study Design

Enrollment
118 participants (estimated)

Arms

  • Arm: Trastuzumab deruxtecan
    Trastuzumab deruxtecan, recommended dose 5.4mg/kg, every 21 days

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years) ]

Central Contacts

Related Studies